Toward Neo-Precaution: A New Approach to Applying the Precautionary Principle to Public Health

American Journal of Bioethics

Volumn 17, Issue 3, 2017, Pages 44-46

  Wilson, Kumanan ^a   Atkinson, Katherine ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; PUBLIC HEALTH; RISK ASSESSMENT;

HUMANS; PUBLIC HEALTH; RISK ASSESSMENT;

EID: 85013080641     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2016.1274792     Document Type: Note

References (13)

1. Alliance of Blood Operators. 2015. Risk-based decision-making framework for blood safety. Available at:https://www.allianceofbloodoperators.org/media/115522/rbdm-framework-2-april-2015-v11-for-website.pdf.
2. Commission of the European Communities. 2000. Communication from the Commission on the precautionary principle. Available at:http://ec.europa.eu/dgs/health_consumer/library/pub/pub07_en.pdf.
3. Kramer, K., H. L., Zaaijer, and M. F., Verweij. 2017. The precautionary principle and the tolerability of blood transfusion risks. American Journal of Bioethics 17 (3):32–43.
4. Lombardi, V. C., F. W., Ruscetti, J., Das Gupta, et al. 2009. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326 (5952):585–89.
5. Wingspread Conference Participants. 1998. Wingspread statement on the precautionary principle. Wingspread Conference, Racine, WI. Available at:https://www.gdrc.org/u-gov/precaution-3.html (accessed January 17, 2017).
6. Wilson, K., 2011. A framework for applying the precautionary principle to transfusion safety. Transfusion Medicine Reviews 25 (3):177–83.
7. Wilson, K., K., Atkinson, and J., Keelan. 2014a. Three decades of MSM donor deferral policies. What have we learned? International Journal of Infectious Disease 18:1–3.
8. Wilson, K., K., Atkinson, and J., Keelan. 2014b. The use of preliminary scientific evidence in public health:A case study of XMRV. PLoS Medicine 11 (4):e1001623.
9. Wilson, K., I., Graham, M. N., Ricketts, C., Dornan, A., Laupacis, and P., Hebert. 2007. Variant Creutzfeldt–Jakob disease and the Canadian Blood System after the tainted blood tragedy. Social Science & Medicine 64 (1):174–85.
10. Wilson, K., P., Hébert, A., Laupacis, et al. 2001. A policy analysis of major decisions relating to Creutzfeldt–Jakob disease and the blood supply. Canadian Medical Association Journal 165 (1):59–65.
11. Wilson, K., and M. N., Ricketts. 2004a. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt–Jakob disease. Transfusion 44 (10):1475–78.
12. Wilson, K., and M. N., Ricketts. 2004b. Transfusion transmission of vCJD:A crisis avoided? Lancet 364 (9433):477–79.
13. Wilson, K., M., Wilson, P., Hébert, and I., Graham. 2003. The application of the precautionary principle to the blood system:The Canadian blood system's vCJD donor deferral policy. Transfusion Medicine Reviews 17 (2):89–94.